Results 241 to 250 of about 1,569,733 (298)

Discovery of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Competing With the Nucleotide Substrate [PDF]

open access: yesAngewandte Chemie - International Edition, 2007
How odd! A new class of non-nucleoside reverse transcriptase inhibitors with a 6-vinylpyrimidine scaffold (1) has been found to inhibit HIV-1 reverse transcriptase (RT) by competition with the nucleotide substrate after binding to the non-nucleoside ...
Giovanni Maga   +2 more
exaly   +3 more sources

Investigational Reverse Transcriptase Inhibitors for the Treatment of HIV

open access: yesExpert Opinion on Investigational Drugs, 2015
INTRODUCTION: While considerable advances have been made in the development of antiretroviral agents, there is still work to be done. Reverse transcriptase inhibitors are important drugs for the treatment of HIV, and considerable research is currently ...
Santosh Kumar   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Related searches:

Mechanism of the action of the inhibitor of reverse transcriptase

Biochemical and Biophysical Research Communications, 1984
An inhibitor of reverse transcriptase of Moloney leukemia virus was reported previously in the cytoplasm of the cultured cells (1). In this report, the mechanism of the inhibition was examined. The inhibitory activity was completely abrogated by treatment at 55 degrees C for 20 min.
M, Rokutanda, S T, Watanabe, Y Y, Maeda
openaire   +2 more sources

HIV-1 reverse transcriptase inhibitors

Applied Microbiology and Biotechnology, 2007
Reverse transcriptase (RT) is one of the three enzymes encoded by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of AIDS. Together with protease inhibitors, drugs inhibiting the RNA- and DNA-dependant DNA polymerase activity of RT are the major components of highly active antiretroviral therapy (HAART), which has dramatically ...
El Safadi, Yazan   +2 more
openaire   +3 more sources

Hepatotoxicity of Nucleoside Reverse Transcriptase Inhibitors

Seminars in Liver Disease, 2003
Hepatotoxicity is an adverse effect of all available classes of antiretrovirals, including nucleoside reverse transcriptase inhibitors (NRTI). A syndrome of hepatic steatosis and lactic acidosis has been recognized as a rare, potentially fatal complication since the advent of NRTI monotherapy in the early 1990s.
Valentina, Montessori   +2 more
openaire   +2 more sources

New Reverse Transcriptase Inhibitors

1999
Reverse transcriptase inhibitors used in the treatment of HIV-1 infection include the nucleoside analogues zidovudine, didanosine, zalcitabine, lamivudine and stavudine. More recently a number of other classes of reverse transcriptase inhibitors have been discovered, and are in various phases of clinical trial. This chapter will focus on the nucleoside
openaire   +2 more sources

HIV Inhibitors Targeted at the Reverse Transcriptase

AIDS Research and Human Retroviruses, 1992
HIV inhibitors targeted at the virus-associated reverse transcriptase (RT) can be divided into two groups, depending on whether they are targeted at the substrate or nonsubstrate binding site. To the first group belong the 2′,3′-dideoxynucleosides (i.e., DDC, DDI), 3′-azido-2′,3′-dideoxynucleosides (i.e., AZT), 3′-fluoro-2′,3 ...
openaire   +2 more sources

Inhibitors of HIV‐1 Reverse Transcriptase

2008
Publisher Summary With the identification of human immunodeficiency virus (HIV)‐1 as the infectious agent leading to acquired immune deficiency syndrome (AIDS), the viral reverse transcriptase (RT) has been a primary focus for drug discovery and development. Currently, two classes of RT inhibitors are used clinically. Nucleoside reverse transcriptase
Tatiana, Ilina, Michael A, Parniak
openaire   +2 more sources

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clinical Drug Investigation, 2007
By the end of 2006, approximately 2.3 million children worldwide were living with HIV infection, representing about 15% of all HIV-infected individuals but only 5-7% of the total population of treated patients worldwide. Despite a general increase in the use of antiretroviral therapy (ART) in resource-limited settings, appropriate care and ART remain ...
GIAQUINTO, CARLO   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy